These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 14644513)

  • 21. Suramin inhibits growth of human osteosarcoma xenografts in nude mice.
    Walz TM; Abdiu A; Wingren S; Smeds S; Larsson SE; Wasteson A
    Cancer Res; 1991 Jul; 51(13):3585-9. PubMed ID: 2054794
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nontoxic suramin treatments enhance docetaxel activity in chemotherapy-pretreated non-small cell lung xenograft tumors.
    Lu Z; Wientjes TS; Au JL
    Pharm Res; 2005 Jul; 22(7):1069-78. PubMed ID: 16028007
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synergistic antitumor effects of regulatory T cell blockade combined with pemetrexed in murine malignant mesothelioma.
    Anraku M; Tagawa T; Wu L; Yun Z; Keshavjee S; Zhang L; Johnston MR; de Perrot M
    J Immunol; 2010 Jul; 185(2):956-66. PubMed ID: 20548032
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of inhibition of multiple steps of angiogenesis in syngeneic murine pleural mesothelioma.
    Merritt RE; Yamada RE; Wasif N; Crystal RG; Korst RJ
    Ann Thorac Surg; 2004 Sep; 78(3):1042-51; discussion 1042-51. PubMed ID: 15337045
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nontoxic doses of suramin enhance activity of paclitaxel against lung metastases.
    Song S; Wientjes MG; Walsh C; Au JL
    Cancer Res; 2001 Aug; 61(16):6145-50. PubMed ID: 11507065
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
    Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antiproliferative effect of suramin on primary cultures of human pheochromocytomas and rat PC12 pheochromocytoma cells.
    Zielke A; Wong MG; Siperstein AE; Clark OH; Rothmund M; Duh QY
    J Surg Oncol; 1997 Sep; 66(1):11-8. PubMed ID: 9290687
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of primary peritoneal mesothelioma by continuous hyperthermic peritoneal perfusion (CHPP).
    Park BJ; Alexander HR; Libutti SK; Wu P; Royalty D; Kranda KC; Bartlett DL
    Ann Surg Oncol; 1999 Sep; 6(6):582-90. PubMed ID: 10493628
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of lung cancer using clinically relevant oral doses of the cyclooxygenase-2 inhibitor rofecoxib: potential value as adjuvant therapy after surgery.
    Tanaka T; Delong PA; Amin K; Henry A; Kruklitis R; Kapoor V; Kaiser LR; Albelda SM
    Ann Surg; 2005 Jan; 241(1):168-78. PubMed ID: 15622005
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Taxol inhibits growth of mesothelioma xenografts.
    Lee JM; Bruckner HW; Szrajer L; Brenne U; Schindelheim G; Andreotti PE
    Anticancer Res; 1995; 15(3):693-6. PubMed ID: 7645945
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Establishment of a murine model of malignant mesothelioma.
    Davis MR; Manning LS; Whitaker D; Garlepp MJ; Robinson BW
    Int J Cancer; 1992 Dec; 52(6):881-6. PubMed ID: 1459729
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Piroxicam and cisplatin in a mouse model of peritoneal mesothelioma.
    Spugnini EP; Cardillo I; Verdina A; Crispi S; Saviozzi S; Calogero R; Nebbioso A; Altucci L; Cortese G; Galati R; Chien J; Shridhar V; Vincenzi B; Citro G; Cognetti F; Sacchi A; Baldi A
    Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6133-43. PubMed ID: 17062690
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Complete inhibition of human ovarian cancer xenografts in nude mice by suramin and cis-diamminedichloroplatinum(II).
    Kikuchi Y; Hirata J; Hisano A; Tode T; Kita T; Nagata I
    Gynecol Oncol; 1995 Jul; 58(1):11-5. PubMed ID: 7789875
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy.
    Feldman AL; Libutti SK; Pingpank JF; Bartlett DL; Beresnev TH; Mavroukakis SM; Steinberg SM; Liewehr DJ; Kleiner DE; Alexander HR
    J Clin Oncol; 2003 Dec; 21(24):4560-7. PubMed ID: 14673042
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nanoparticle tumor localization, disruption of autophagosomal trafficking, and prolonged drug delivery improve survival in peritoneal mesothelioma.
    Liu R; Colby AH; Gilmore D; Schulz M; Zeng J; Padera RF; Shirihai O; Grinstaff MW; Colson YL
    Biomaterials; 2016 Sep; 102():175-86. PubMed ID: 27343465
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Suramin as adjuvant therapy with radical prostatectomy.
    Saffrin R; Chou P; Ray V; Shaw M; Rubenstein M; Guinan P
    Prostate; 1996 May; 28(5):325-7. PubMed ID: 8610060
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Suramin augments the antitumor and antimetastatic activity of pentoxifylline in B16F10 melanoma.
    Dua P; Ingle A; Gude RP
    Int J Cancer; 2007 Oct; 121(7):1600-8. PubMed ID: 17582610
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low dose suramin as a chemosensitizer of bladder cancer to mitomycin C.
    Xin Y; Lyness G; Chen D; Song S; Wientjes MG; Au JL
    J Urol; 2005 Jul; 174(1):322-7. PubMed ID: 15947683
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chemotherapy and serum hyaluronic acid levels in malignant peritoneal mesothelioma.
    Hotta T; Taniguchi K; Kobayashi Y; Johata K; Sahara M; Naka T; Tanimura H; Tsubota YT
    Hepatogastroenterology; 2004; 51(58):1073-83. PubMed ID: 15239250
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Paclitaxel-loaded expansile nanoparticles in a multimodal treatment model of malignant mesothelioma.
    Schulz MD; Zubris KA; Wade JE; Padera RF; Xu X; Grinstaff MW; Colson YL
    Ann Thorac Surg; 2011 Dec; 92(6):2007-13; discussion 2013-4. PubMed ID: 21963198
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.